[Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy]

Med Klin (Munich). 1996 Jul 15;91(7):479-85.
[Article in German]

Abstract

Aim: The costs of drug treatment were evaluated for Parkinson's disease, focal dystonias and epilepsy.

Methods: Retrospective analysis over a period of 12 months of 785 patients who visited regularly a neurological out-patient department.

Results: Drug treatment caused a mean annual expenditure of DM 3,920.- (US-($) 2590, pounds 1690) for Parkinson's disease (n = 409), DM 3,620.- (US-($) 2390; pounds 1550) for focal dystonias (n = 140) and DM 660.- (US-($) 435, pounds 280) for hemifacial spasm (n = 35) per patient.- In Parkinson's disease costs are dependent on the extent of the disease, the type involved and the presence or absence of motor fluctuations. In Hoehn and Yahr stage I we calculated costs of DM 2,230.- (US-($) 1470; pounds 960), in contrast to DM 11,870.- (US-($) 7830; pounds 5100) in Hoehn and Yahr stage V. The occurrence of fluctuations in motor ability increased annual costs to DM 6,010.- (US-($) 3970, pounds 2580); patients' treatment without motor fluctuations was cheaper (DM 2,700.-; US-($) 1780, pounds 1160).- The annual treatment costs of focal dystonias and facial hemispasm varied due to the location of the involuntary movement and the extent of symptoms: DM 4,900.- (US-($) 3300; pounds 2100) were calculated for the treatment of cervical dystonias, DM 1,480.- (US-($) 930; pounds 600) for the treatment of blepharo-spasm (oromandibular dystonia: DM 1,710.-; US-($) 1200; pounds 800) and DM 600.- (US-($) 470; pounds 300) for the treatment of facial hemispasm.- The drug treatment of epilepsy caused mean costs of DM 1,740.- (US-($) 1160; pounds 750) per year. There were marked differences concerning the different epileptic syndromes and types of seizure.

Conclusion: Costs of drug treatment varied considerably in the three diseases depending on the course, the type and the different forms of the respective disease.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anticonvulsants / economics*
  • Anticonvulsants / therapeutic use
  • Antiparkinson Agents / economics*
  • Antiparkinson Agents / therapeutic use
  • Child
  • Child, Preschool
  • Cross-Cultural Comparison
  • Dystonia / drug therapy
  • Dystonia / economics*
  • Epilepsy / drug therapy
  • Epilepsy / economics*
  • Female
  • Germany
  • Humans
  • Male
  • Middle Aged
  • Parasympatholytics / economics*
  • Parasympatholytics / therapeutic use
  • Parkinson Disease / drug therapy
  • Parkinson Disease / economics*
  • United Kingdom
  • United States

Substances

  • Anticonvulsants
  • Antiparkinson Agents
  • Parasympatholytics